Hereditary hemorrhagic telangiectasia/avastin.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19998344.
- Also identified by DOI 10.1002/lary.20757.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This is the first scientific report of hereditary hemorrhagic telangiectasia (HHT) epistaxis treatment by intranasal spraying of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin). Epistaxis in patients with HHT is a morbid, mortal condition that is difficult and unpleasant to manage. Nasal telangiectasia growth is modulated by VEGF, which is elevated in HHT patients. Bevacizumab is a VEGF inhibitor that diminishes epistaxis when administered intravenously or injected locally, or as reported here when sprayed topically onto the nasal mucosa.
Medical subject headings
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Epistaxis
- Telangiectasia, Hereditary Hemorrhagic
- Vascular Endothelial Growth Factor A